Tremfya

Tremfya (guselkumab) is a biologic approved for the treatment of psoriasis and psoriatic arthritis. Tremfya was approved by the FDA in 2017 for adult patients with active psoriatic arthritis.

What is Tremfya?

Tremfya (also known by its generic name guselkumab) was approved by the FDA in July 2017 for the treatment of moderate-to-severe plaque psoriasis in adults. In July 2020, the FDA also approved Tremfya to treat adults with active psoriatic arthritis.

Tremfya is given by injection under the skin at week 0 (the first week of treatment) and week 4, and then every 8 weeks afterwards.

To learn more, please visit the Tremfya website.

A man smiles while stretching outside with others.

Psoriatic Arthritis Patients Have a New Option

FDA Approves Tremfya for the Treatment of Psoriatic Arthritis.

Find out more
Illustrated graphic of people around a rocket ship and computer.

Advance Online

Get the latest news on new treatment options from NPF.

Stay up to date

Learn More About Your Treatment Options

The Patient Navigation Center is here to provide personalized information about your psoriasis and psoriatic arthritis treatment.

Contact a Patient Navigator today

Stay in the Know.

Expert tips, can’t-miss events and the latest news, straight to your inbox.

National Health Council Standards of ExcellenceCharity NavigatorMy Psoriasis Team logo

Copyright © 1996-2020 National Psoriasis Foundation/USA


Duplication, rebroadcast, republication or other use of content appearing on this website is prohibited without written permission of the National Psoriasis Foundation (NPF).


NPF does not endorse or accept any responsibility for the content of external websites.


NPF does not endorse any specific treatments or medications for psoriasis and psoriatic arthritis.

We use cookies to offer you a better experience and analyze our site traffic. By continuing to use this website, you consent to the use of cookies in accordance with our Privacy Policy.